Press Release 2013Press Release 2013Press Release 2013Press Release 2013Press Release 2013

Good vibes bloom on the Medical Cannabis Bike Tour
3 days…. 385km… €50,000…
Thanks to the second annual Medical Cannabis Bike Tour, €50,000 has been raised to fund medical research into the cancer fighting properties of cannabis.With cyclists from all over Europe taking part, the MC Bike Tour was an epic 385km adventure through the mountains from Madrid to the GrowMed Expo in Valencia, April 15-18. Ranging in age from 18 to 70, the group included cannabis users and non-users, as well as those who had lost family and friends to cancer, all participating in the tour united by a great cause. The brainchild of Luc Krol (Paradise Seeds) and Matej Munih (Snail Rolling Papers), The Medical Cannabis Bike Tour is all about promoting research into the medical benefits of the plant. In its second year, the MC Bike Tour saw 20 cyclists join the cause and the team have already been inundated with enquiries from people wanting to ride in next year’s tour. Luc Krol said. “It has been a fantastic ride, a great adventure with good vibes and brilliant people. This is only going to get bigger! We’re bringing the message that cannabis has medical properties that can cure cancer. If Governments won’t fund research, then it’s up to us to do it on our own.” After three days, the bike tour arrived to a noisy reception at GrowMed, Europe’s medical cannabis expo. Here, a check for €50,000 was handed to Dr Guillermo Vallesco who, along with Dr Manuel Guzman, has been pioneering studies in the use of cannabinoids to treat cancer at Madrid’s Complutense University. Luc added, “We are very grateful to the sponsors who have helped us to raise such a significant amount of money. This money will fund important research into the use of cannabis in treating cancer.” Dr Guillermo said; “We would like to thank the Medical Cannabis Bike Tour for their donation. The money will help us in our studies of the effects of cannabinoids, on their own and in combination with other agents, in developing therapies for the future treatment of cancer patients.” End